Pathogenesis and treatment of type 2 (noninsulin-dependent) diabetes mellitus (NIDDM)

Hormone and Metabolic Research

Volumn 28, Issue 9, 1996, Pages 404-412

  Gerich, J E ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

NIDDM; Pathogenesis; Treatment

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; INSULIN; SULFONYLUREA DERIVATIVE;

CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; WEIGHT GAIN;

EID: 0029851834     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979828     Document Type: Conference Paper

References (53)

1. Abraira, C., J. Colwell, F. Nuttall, C. Sawin, N. Nagel, J. Comstock, N. Emanuelle, S. Levin, W. Henderson, H. Lee, VA CSDM Group: Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Diabetes Care 18: 1113-1123 (1995)
2. ADA Consensus Panel: The pharmacologic treatment of hyperglycemia in NIDDM. Diabetes Care 18: 1510-1518 (1995)
3. Bak, J., N. Moller, O. Schmitz, A. Saaek, O. Pedersen: In vivo action and muscle glycogen synthase activity in type II (noninsulin dependent) diabetes mellitus: effects of diet treatment. Diabetologia 35: 777-784 (1992)
4. Bailey, C.: Metformin - an update. Gen. Pharmacol. 24: 1299-1309 (1993)
5. Banerji, M., R. Chaiken, D. Gordon, J. Kral, H. Lebovitz: Does intraabdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes 44: 141-146 (1995)
6. Beck-Nielsen, H., O. Pedersen, H. Lindskov: Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol. 90: 103-112 (1979)
7. Bennet, P.: In: Diabetes Mellitus (H. Tifkin and D. Porte, eds.), Elsevier, NY 1990, pp. 357-377
8. Bressler, R., D. Johnson: New pharmacological approaches to therapy of NIDDM. Diabetes Care 15: 792-805 (1992)
9. Brownlee, M.: Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15: 1835-1843 (1992)
10. Bruce, D., D. Chisholm, L. Storlien: Physiologic importance of deficiency in early prandila insulin secretion in noninsulin-dependent diabetes. Diabetes 37: 736-744 (1988)
11. Calles-Escandon, J., D. Robbins: Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 36: 1167-1172 (1987)
12. Coniff, R., J. Shapiro, T. Seaton, G. Bray: Multicenter, placebo-controlled trial comparing acarbonse (BAYg5421) with placebo, tulbutamide and tolbutamide-plus-acarbose in non-insulin dependent diabetes mellitus. JAMA 98: 443-451, 1995.
13. Consoli, A., N. Nurjhan, F. Capani, J. Gerich: Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38: 550-561 (1989)
14. Damm, P., C. Kuhl, P. Hornnes, L. Molsted-Pedersen: A longitudinal study of plasma insulin and glucagon in women with gestational diabetes. Diabetes Care 18: 654-665 (1995)
15. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N. Eng. J. Med. 329: 977-986 (1993)
16. DeFronzo, R.: The triumvirate: β-.cell, muscle, and liver: a collusion responsible for NIDDM. Diabetes 37: 667-687 (1988)
17. Dinneen, S., J. Gerich, R. Rizza: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N. Eng. J. Med. 327: 707-713 (1992)
18. Dornhorst, A., S. Edwards, J. Nicholls, V. Anyaoku, D. McLaren, K. Heslop, R. Elkeles, R. Beard, D. Johnston: A defect in insulin release in women at risk for future non-insulin-dependent diabetes. Clin. Sci. 81: 195-199 (1991)
19. Eastman, R., R. Silverman, M. Harris, J. Javitt, Y. Chiang, P. Gorden: Lessening the burden of diabetes. Diabetes Care 16: 1095-1102 (1993)
20. Foley, J.: Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes. Diabetes Care 15: 773-784 (1992)
21. Freidenberg, G., D. Reichart, J. Olefsky, R. Henry: Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. J. Clin. Invest. 82: 1398-1406 (1988)
22. Fuller, J., M. Shipley, J. Rose, R. Jarrett, H. Keen: Mortality from coronary heart disease and stroke in relation to degree of hyperglycemia: the Whitehall Study. Br. Med. J. 27: 867-870 (1983)
23. Gerich, J.: Oral hypoglycemic agents. N. Engl. J. Med. 321: 1231-1245 (1989)
24. Greene, D., A. Sima, M. Stevens, E. Feldman, P. Killen, D. Henry, T. Thomas, J. Danenberg, S. Lattimer: Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diabetes Metab. Rev. 9: 189-217 (1993)
25. Gutnick, M., C. Orskov, J. Holst, B. Ahren, S. Effendic: Antidiabetogenic effects of glucagon-like peptide-1 (7 - 36) oncide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326: 1316-1322 (1992)
26. Hayes, T., J. Harries: Randomized controlled trial of routine hospistal clinic care versus routine general practice care for type 2 diabetes. Brit. Med. J. 289: 728-730 (1984)
27. Hofman, C., K. Lorenz, S. Braithwaite, J. Colca, B. Palazuk, G. Hotamisligil, B. Spiegelman: Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134: 264-270 (1994)
28. Hotamisligil, G., D. Murray, L. Choy, B. Spiegelman: Tumor necrosis factor α inhibits signalling from the insulin receptor. Proc. Natl. Acad. Sci. USA 91: 4854-4858 (1994)
29. Hotamisligil, G., N. Shargill, B. Spiegelman: Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259: 87-90 (1993)
30. Hotamisligil, G., B. Spiegelman: Tumor necrosis factor α: a key component of the obesity - diabetes link. Diabetes 43: 1271-1278 (1994)
31. Knuiman, M., T. Welborn, K. McCann, K. Stanton, I. Constable: Prevalence and diabetic complications in relation to risk factors. Diabetes 35: 1332-1339 (1986)
32. McKibbin, P., S. Cotton, S. McMillan, B. Holloway, R. Mayers, H. McCarthy, G. Williams: Altered neuropeptide Y concentrations in specific hypothalamic regions of obese (fa/fa) Zucker rats. Possible relationship to obesity and neuroendocrine disturbances. Diabetes 10: 1423-1429 (1991)
33. Mitrakou, A., D. Kelley, T. Venemann, T. Jenssen, T. Pangburn, J. Reilly, J. Gerich: Contribution of abnormal muscle and liver glucose metabolism in postprandial hyperglycemia in noninsulin-dependent diabetes mellitus. Diabetes 39: 1381-1390 (1990)
34. Mitrakou, A., D. Kelley, T. Veneman, T. Pangburn, J. Reilly, J. Gerich: Role of reduced suppression of hepatic glucose output and diminished early insulin release in impaired glucose tolerance. N. Eng. J. Med. 326: 22-29 (1992)
35. Nathan, D., D. Singer, J. Godine, C. Harrington, L. Perlmuter: Retinopathy in older Type II diabetics: Association with glucose control. Diabetes 35: 797-801 (1986)
36. Nauck, M., E. Bartels, C. Orskov, R. Ebert, W. Creutzfeldt: Additive insulinotropic effects of exogeneous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1 (7-36) amide infused at near physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76: 912-917, 1993.
37. Nolan, J., B. Ludvik, P. Beerdsen, M. Joyce, J. Olefsky: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331: 1188-1193 (1994)
38. Ohkubo, Y., H. Kishikawa, E. Araki, T. Miyata, S. Isami, S. Motoyoshi, Y. Kojima, N. Furugoshi, M. Shichiri: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patient with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28: 103-117 (1995)
39. Orskov, C., J. Jeppesen, S. Madsbad, J. Holst: Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin. Invest. 87: 412-415 (1991)
40. Pelleymounter, M., M. Cullen, M. Baker, R. Hecht, D. Winters, T. Boone, F. Collins: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269: 540-543 (1995)
41. Pimenta, W., M. Kortytkowski, A. Mitrakou, T. Jenssen, H. Yki-Jarvinen, W. Evron, C. Dailey, J. Gerich: Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. JAMA 273: 1855-1861 (1995)
42. Rachman, J., R. Turner: Drugs on the horizon for treatment of type 2 diabetes. Diabetic Medicine 12: 467-578 (1995)
43. Randle, P., P. Garland, C. Hales, E. Newsholme: The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789 (1963)
44. Rubin, R., W. Altman, D. Mendelson: Health care expenditures for people with diabetes mellitus. J. Clin. Endocrinol. Metab. 78: 809A-809F (1994)
45. Rudenski, A., D. Hadden, A. Atkinson, L. Kennedy, D. Matthews, J. Merrett, B. Pockcaj, R. Turner: Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabetic Med. 5: 36-41 (1988)
46. Scheen, A., M. Castello, P. Lefebvre: Combination of oral antidiabetic drugs and insulin in the treatment of noninsulin dependent diabetes. Acta Clinica Belgica 48: 259-268 (1993)
47. Shank, M., S. DelPrato, R. DeFronzo: Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes 44: 1265-1275 (1995)
48. Stevenson, R., E. Gibbs, D. Kreutter, R. McPherson, D. Clark, B. Hulin, S. Goldstein, J. Parker, A. Swick, J. Treadway, D. Hargrave, G. Shulman: The thiazolidinedione drug series. The Diabetes Annual/9 (Marshall, S., Home, P., Rizza, R., eds.) Elsevier Science, NY 1995, pp. 175-191
49. Stumvoll, M., N. Murjhan, G. Perrello, G. Dailey, J. Gluch: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333: 550-554, 1995.
50. Taskinen, M., T. Kuusi, E. Helve, Nikkila, H. Yki-Jarvinen: Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8: 168-177 (1988)
51. United Kingdom Prospective Diabetes Study Group: United Kingdom prospective diabetes study /UKPDS) 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin or metformin in patients with new diagnosed non-insulin dependent diabetes followed for three years. Br. Med. J. 310: 83-88 (1995)
52. Yki-Jarvinen, H.: Glucose toxicity. Endocrine Reviews 13: 415-431 (1992)
53. Zimmet, P., D. McCarty: The NIDDM epidemic: global estimates and projections - a into the crystal ball. IDF Bulletin 40: 8-17 (1995)